Illumina (XSWX:ILMN) Marketable Securities: CHF52 Mil (As of Mar. 2026)


XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF143.95
GF Value CHF105.51
! 7 Warning Signs
View Full Analysis

What is Illumina Marketable Securities?

Illumina XSWX:ILMN -0.79% 76 Marketable Securities is CHF52 Mil as of Mar. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Illumina's Marketable Securities for the quarter that ended in Mar. 2026 was CHF52 Mil.

Illumina's annual Marketable Securities increased from Dec. 2023 (CHF5 Mil) to Dec. 2024 (CHF83 Mil) and increased from Dec. 2024 (CHF83 Mil) to Dec. 2025 (CHF171 Mil).

Illumina  (XSWX:ILMN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Illumina Marketable Securities Related Terms

Illumina Marketable Securities Historical Data

* Premium members only.

The historical data trend for Illumina's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Marketable Securities Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.55 24.22 5.19 82.92 171.33

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.57 179.72 181.51 171.33 51.96
XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of CHF52 Mil mean?
Illumina (XSWX:ILMN) has a Marketable Securities of CHF52 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Illumina and its competitors.
Is Illumina's Marketable Securities too high?
Illumina's current Marketable Securities is CHF52 Mil. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Marketable Securities compare to MTD and DGX?
Illumina's Marketable Securities of CHF52 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Illumina and its competitors. Illumina's current Marketable Securities is CHF52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Marketable Securities of CHF52 Mil. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Marketable Securities is CHF52 Mil. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Marketable Securities is CHF52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.

Key valuation signals for XSWX:ILMN:

  • Marketable Securities: CHF52 Mil
  • GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF143.95
Price
CHF105.51
GF Value